Nomori H, Horio H, Kobayashi R, Morinaga S, Hirabayashi Y
Dept of Surgery, Saiseikai Central Hospital, Tokyo, Japan.
Eur Respir J. 1995 Oct;8(10):1654-7. doi: 10.1183/09031936.95.08101654.
As many antineoplastic drugs can cause injury to alveolar pneumocytes, Clara cells (nonciliated, nonmucous epithelial cells of the bronchioles) may also be damaged by such drugs. Protein 1 (P1) is an alpha-microprotein secreted by Clara cells. The effect of antineoplastic drugs on Clara cells is examined by the measurement of serum levels of P1 in patients with lung cancer receiving chemotherapy. Serum levels of P1 were studied in 36 patients with lung cancer, before chemotherapy and 5-7, 10-12 and 14-18 days after chemotherapy. One hundred and eight healthy subjects, matched by sex and age, acted as controls. There was no significant difference in P1 serum levels between patients with lung cancer and healthy controls. P1 serum levels decreased significantly 5-7 and 10-12 days after chemotherapy, recovering thereafter. We conclude that P1 serum levels do not differ between lung cancer patients and healthy controls, and that antineoplastic drugs inhibit the synthesis or secretion of P1 by Clara cells in the early period after the administration of medication.
由于许多抗肿瘤药物会损伤肺泡上皮细胞，克拉拉细胞（细支气管的无纤毛、无黏液上皮细胞）也可能被此类药物损害。蛋白1（P1）是克拉拉细胞分泌的一种α微蛋白。通过测量接受化疗的肺癌患者血清中P1的水平，来研究抗肿瘤药物对克拉拉细胞的影响。对36例肺癌患者在化疗前以及化疗后5 - 7天、10 - 12天和14 - 18天的血清P1水平进行了研究。108名年龄和性别相匹配的健康受试者作为对照。肺癌患者与健康对照者的血清P1水平无显著差异。化疗后5 - 7天和10 - 12天血清P1水平显著下降，随后恢复。我们得出结论，肺癌患者与健康对照者的血清P1水平没有差异，并且抗肿瘤药物在用药后的早期会抑制克拉拉细胞合成或分泌P1。
